Dernière mise à jour : 02 septembre 2016
Détails
FichiersGeneric Name:
Bortezomib
État du projet:
Terminé
Domaine thérapeutique:
Multiple Myeloma
Fabricant:
Janssen
Brand Name:
Velcade
Gamme de produits:
Examen en vue du remboursement
Strength:
3.5mg/vial
Tumour Type:
Myeloma
Indications:
Multiple Myeloma
Funding Request:
For the treatment of patients with multiple myeloma pre-autologous stem cell transplantation in combination therapy and post-autologous stem cell transplantation as monotherapy
Review Status:
Complete
Pre Noc Submission:
Yes
Date NOC Issued:
Sponsor:
Cancer Care Ontario Hematology Disease Site Group
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Couvrir le remboursement
pERC Meeting:
Final Recommendation Issued:
Fichiers
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Dernière mise à jour : 02 septembre 2016